Novel Immunotherapy Agents for Acute Lymphoblastic Leukaemia
Acute lymphoblastic leukaemia (ALL) in adults has a survival rate of 40–50% at 5 years, with a high relapse rate after first-line chemotherapy. After relapse, results with salvage therapy are currently unsatisfactory. Therefore, both the optimisation of front-line therapy to reduce relapse incidence...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2017-08-01
|
| Series: | European Medical Journal |
| Subjects: | |
| Online Access: | https://www.emjreviews.com/hematology/article/novel-immunotherapy-agents-for-acute-lymphoblastic-leukaemia/ |